This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper
British Journal of Cancer Open Access 22 July 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Acknowledgements
The authors gratefully acknowledge the contributions of U. Schulze, P. Tollman and L. Henry to this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on strategies in oncology, among other therapeutic areas. The research for this specific article was funded by BCG's Health Care practice.
Supplementary information
Supplementary information S1 (box)
Dataset and analysis methods (PDF 102 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Cavnar, S., Valencia, P., Brock, J. et al. The immuno-oncology race: myths and emerging realities. Nat Rev Drug Discov 16, 83–84 (2017). https://doi.org/10.1038/nrd.2016.279
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.279
This article is cited by
-
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper
British Journal of Cancer (2020)